Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Dana-Farber Cancer Institute
Information provided by (Responsible Party):
Yi-Bin A. Chen, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01398501
First received: July 19, 2011
Last updated: January 14, 2016
Last verified: January 2016